Research Analysts Offer Predictions for ProPhase Labs, Inc.’s Q1 2025 Earnings (NASDAQ:PRPH)

ProPhase Labs, Inc. (NASDAQ:PRPH) – Research analysts at Diamond Equity issued their Q1 2025 earnings per share (EPS) estimates for ProPhase Labs in a research report issued on Monday, April 22nd. Diamond Equity analyst H. Diamond anticipates that the company will earn $0.10 per share for the quarter. The consensus estimate for ProPhase Labs’ current full-year earnings is ($0.88) per share. Diamond Equity also issued estimates for ProPhase Labs’ Q2 2025 earnings at $0.12 EPS, Q3 2025 earnings at $0.12 EPS and Q4 2025 earnings at $0.14 EPS.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $11.00 price target on shares of ProPhase Labs in a report on Wednesday, February 21st.

ProPhase Labs Stock Up 5.3 %

Shares of ProPhase Labs stock opened at $5.16 on Wednesday. The company has a current ratio of 2.28, a quick ratio of 2.10 and a debt-to-equity ratio of 0.29. ProPhase Labs has a 12-month low of $4.05 and a 12-month high of $9.94. The firm’s 50-day moving average price is $5.53 and its two-hundred day moving average price is $5.00.

ProPhase Labs (NASDAQ:PRPH) last released its earnings results on Thursday, March 28th. The company reported ($0.51) earnings per share for the quarter. ProPhase Labs had a negative net margin of 37.81% and a negative return on equity of 29.83%. The company had revenue of $3.50 million for the quarter, compared to the consensus estimate of $10.71 million.

Institutional Trading of ProPhase Labs

Several institutional investors and hedge funds have recently modified their holdings of PRPH. Tower Research Capital LLC TRC grew its position in ProPhase Labs by 50.3% in the fourth quarter. Tower Research Capital LLC TRC now owns 15,010 shares of the company’s stock valued at $68,000 after acquiring an additional 5,026 shares during the last quarter. SVB Wealth LLC bought a new position in shares of ProPhase Labs in the third quarter worth about $208,000. Finally, HighTower Advisors LLC acquired a new stake in shares of ProPhase Labs in the 3rd quarter valued at approximately $756,000. 9.45% of the stock is currently owned by institutional investors.

ProPhase Labs Company Profile

ProPhase Labs, Inc develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster.